Dr. Katsanis's laboratory has established various experimental haploidentical hematopoietic cell transplantation (HHCT) models and is studying novel conditioning regimens and agents that can be applied following transplantation to limit graft versus host disease (GvHD) while permitting donor chimerism, immune reconstitution and graft versus tumor effects. The mechanisms of action of these regimens are being investigated in leukemia and solid tumor models. His lab's objective is the translation of innovative HHCT approaches into Phase I/II trials for pediatric and adult patients with advanced hematologic malignancies and refractory solid tumors.

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Jazz Pharmaceuticals
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube


Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect


Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811